Close
FINDING CURES TOGETHER<sup>SM</sup>

Advances in Prostate Cancer Research

​Program 


Thursday, March 12


Friday, March 13

Hypoxia-inducible factors and the lethal cancer phenotype
Gregg L. Semenza, Johns Hopkins University School of Medicine, Baltimore, Maryland


Opening Reception
6-7:30 p.m.


Top of page


Friday, March 13

Continental Breakfast
7-8 a.m.


Plenary Session 1: Biological Drivers of Risk - Carcinogenesis and Early Prostate Cancer
Session Chair: Rosalind A. Eeles, Institute of Cancer Research, Sutton, England
8-10 a.m.

Title to be announced
Rosalind A. Eeles, Institute of Cancer Research, Sutton, United Kingdom

Title to be announced
Christopher A. Haiman, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California

Title to be announced
Veda N. Giri, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Multiplex functional interrogation of combinations of genetic alterations in prostate cancer*
Shan Li, Fred Hutchinson Cancer Research Center, Seattle, Washington

The three-dimensional genome atlas of primary prostate cancer*
Stanley Zhou, Princess Margaret Cancer Centre, Toronto, Ontario, Canada


Break
10-10:30 a.m.


Plenary Session 2: DNA Repair
Session Chair: Robert G. Bristow, University of Manchester, Manchester, England
10:30 a.m.-12:30 p.m.

Title to be announced
Karen E. Knudsen, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, Pennsylvania 

Title to be announced
Robert G. Bristow, University of Manchester, Manchester, United Kingdom

Precision therapy with DNA-targeted drugs 
Yves G. Pommier, National Cancer Institute, Bethesda, Maryland

Targeting PARP-1 and PARP-2 in prostate cancer beyond BRCAness*
Li Jia, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts

Hallmarks of epigenomic regulation in advanced prostate cancer*
David Quigley, University of California at San Francisco, San Francisco, California


Free Time / Lunch on Own
12:30-2:30 p.m.


Plenary Session 3: Drivers of Tumor Evolution and Plasticity
Session Chair: Himisha Beltran, Dana-Farber Cancer Institute, Boston, Massachusetts
2:30-4:30 p.m.

Prostate cancer therapeutics create new species and new targets
Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, Washington 

Title to be announced
Himisha Beltran, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Felix Y. Feng, University of California San Francisco, San Francisco, California 

Defining and dissecting drivers of resistance to neoadjuvant chemohormonal therapy using PSMA PET/MRI in multi-focal prostate cancer*
Joshua Lang, University of Wisconsin, Madison, Wisconsin

The Microphthalmia Transcription Factor (MITF) contributes to the aggressiveness and acquisition of castration resistance in lethal prostate cancer*
Josep Domingo-Domenech, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania


Poster Session A / Reception
4:30-7 p.m.


Top of page


Saturday, March 14

Continental Breakfast
7-8 a.m.


Plenary Session 4: Advances in Detection and Diagnosis
Session Chair: Beatrice S. Knudsen, Cedars-Sinai Medical Center, New York, New York
8-10 a.m.

PSA: How a great marker turned into a public health fiasco (and how to turn it back)
Andrew Vickers, Memorial Sloan Kettering Cancer Center, New York, New York

Pathology A.I. to identify novel phenotype: Genotype associations in aggressive prostate cancer
Beatrice S. Knudsen, Cedars-Sinai Medical Center, New York, New York

Title to be announced
Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Using deep learning to improve Gleason grading of prostate cancer specimens
Craig Mermel, Google Health, Palo Alto, California


Break
10-10:30 a.m.


Plenary Session 5: Hormone Receptor Signaling and Crosstalk
Session Chair: Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, Massachusetts
10:30 a.m.-12:30 p.m.

Landscape of AR gene rearrangements in prostate cancer
Scott M. Dehm, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota 

Intense androgen deprivation therapy with prostatectomy for localized high-risk prostate cancer
Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, Massachusetts

Androgen receptor switch in treatment resistance
Amina Zoubeidi, Vancouver Prostate Center, Vancouver, BC, Canada

The androgen receptor (AR) regulates a druggable translational regulon in AR-deficient prostate cancer*
Andrew Hsieh, Fred Hutchinson Cancer Research Center, Seattle, Washington

GR antagonist ORIC-101 overcomes glucocorticoid-driven resistance to enzalutamide in prostate cancer models*
Anneleen Daemen, ORIC Pharmaceuticals, South San Francisco, California


Poster Session B / Lunch
12:30-3 p.m.


Plenary Session 6: Metabolism
Session Chair: Donald P. McDonnell, Duke University Medical Center, Durham, North Carolina
3-5 p.m.

Steroid metabolism drivers of prostate cancer resistance to hormonal therapies
Nima Sharifi, The Cleveland Clinic Lerner Research Institute, Cleveland, Ohio

Title to be announced
Massimo Loda, Weill Cornell Medical College, New York, New York 

Therapeutic exploitation of nuclear receptors/nuclear receptor-regulated pathways in cancer
Donald P. McDonnell, Duke University Medical Center, Durham, North Carolina

NAD+ metabolism as a potential therapeutic vulnerability in neuroendocrine prostate cancer*
Andrew Goldstein, University of California, Los Angeles, Los Angeles, California

E2F1 recalibration after RB loss drives altered metabolism in castration-resistant prostate cancer (CRPC)*
Amy Mandigo, Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, Pennsylvania


Break
5-5:15 p.m.


Special Session: Proffered Talks from Highly Rated Abstracts
Session Chair: Veda N. Giri, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
5:15-6:15 p.m.

Targeting AR addiction through CDK7/MED1 axis in castration-resistant prostate cancer*
Irfan Asangani, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennyslvania

Epitranscriptomic regulation of androgen receptor signaling by N6-adenosine-methyltransferase in prostate cancer*
Kellie Cotter, University of Bern, Bern, Switzerland

RET kinase as a driver of neuroendocrine prostate cancer*
Justin Drake, University of Minnesota, Minneapolis, Minnesota

CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis*
Michael Augello, Weill Cornell Medicine, New York, New York


Evening on Own
6:15 p.m.-




Sunday, March 15

Continental Breakfast
7-8 a.m.


Plenary Session 7: Tumor and Immune Microenvironment
Session Chair: James L. Gulley, National Cancer Institute, Bethesda, Maryland
8-10 a.m.

Chromosomal instability and inflammation-driven metastasis in cancer
Samuel F. Bakhoum, Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced
Charles G. Drake, Columbia University Medical Center, New York, New York

Tumor microenvironment: The immunotherapy detective's treasure trove
James L. Gulley, National Cancer Institute, Bethesda, Maryland

Therapeutic potential of targeting macrophages in castration resistance prostate cancer*
Asmaa Elkenawi, H. Lee Moffitt Cancer Center, Tampa, Florida

Loss of myeloid BMPR1a alters differentiation and reduces mouse prostate cancer growth*
Claire Ihle, University of Colorado Anschutz, Aurora, Colorado


Break
10-10:30 a.m.


Plenary Session 8: Novel Targets
Session Chair: Marco M. Gottardis, Janssen R&D, Spring House, Pennsylvania
10:30 a.m.-12:30 p.m.

Next-generation therapeutics in the face of the changing landscape of prostate cancer biology
Marco M. Gottardis, Janssen R&D, Spring House, Pennsylvania

Title to be announced
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Michigan

Optimizing precision care for patients with advanced prostate cancer: From patient identification to therapy
Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, Michigan

Identification of prostate-restricted epithelial antigens for transgenic T cell adoptive therapy against prostate cancer*
Diana DeLucia, Fred Hutchinson Cancer Research Center, Seattle, Washington

Selective inhibition of transcription factor BRN2 as a treatment strategy for small-cell prostate cancer*
Daksh Thaper, University of British Columbia, Vancouver, BC, Canada



Closing Keynote
12:30-1:30 p.m.

Title to be announced
Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom


Closing Remarks
1:30 p.m.

Felix Y. Feng, University of California San Francisco, San Francisco, California
Karen E. Knudsen, Thomas Jefferson University Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, Michigan

*Short talk from proffered abstract